Sarepta Therapeutics announced research agreement with U.S. DoD to evaluate multiple constructs from proprietary RNA platform as treatments for COVID-19
| | | |

Sarepta Therapeutics announced research agreement with U.S. DoD to evaluate multiple constructs from proprietary RNA platform as treatments for COVID-19

On Apr. 28, 2020, Sarepta Therapeutics announced the Company and the USAMRIID, the Department of Defense’s lead laboratory…